上海康德莱企业发展集团股份有限公司的主营业务是医用穿刺针、医用输注器械等医疗器械的研发、生 产、销售和服务。公司的主要产品是穿刺护理类、输液导管类、留置输注类、穿刺介入类、医疗美容 类、药包材类、动物医疗类、胰岛素给药类、标本采集类、有源医疗器械类。公司总部的研发机构为上 海市级企业技术中心，子公司浙江康德莱设立了省级穿刺医疗器械研究院，子公司广东医械集团的研发 中心被认定为广东省穿刺类医疗器械工程技术研究中心及珠海市企业技术中心。 最新一期业绩显示，2025年一季报，公司实现营业收入5.48亿元，同比-3.82%；净利润6070.42万元，同 比0.28%，销售毛利率32.02%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)8康德莱18.2218.241.5139.27亿行业平均 55.7651.784.91117.92亿行业中值39.1439.592.8556.79亿1九安医疗11.1811.310.88188.72亿2英科医疗 14.7815.931.32233.49亿3山东药玻16.1716.211.86152.90亿4新华医疗16.3115.111.33104.53亿5振德医疗 17.0 ...

从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均55.70倍，行业中值39.08倍，康德莱排名 第41位。 最新一期业绩显示，2025年一季报，公司实现营业收入5.48亿元，同比-3.82%；净利润6070.42万元，同 比0.28%，销售毛利率32.02%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)10康德莱18.7118.721.5540.32亿行业平均 55.7051.864.84117.31亿行业中值39.0838.492.8857.46亿1九安医疗11.1411.270.88188.05亿2英科医疗 15.5716.791.39246.03亿3山东药玻16.0616.111.85151.90亿4振德医疗16.3115.371.0459.21亿5新华医疗 16.4415.241.34105.38亿6奥美医疗17.0016.661.7561.43亿7九强生物17.7016.462.1787.65亿8维力医疗 18.1019.342.2842.44亿9奥泰生物18.4319.441.4958.79亿11鱼跃医疗19.9619.582.70353.47亿12安图生物 20.5219.59 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Kangdai, a company in the medical device industry, which is currently facing challenges with a lower-than-average PE ratio compared to its peers [1][2] - As of May 22, Kangdai's closing price was 7.35 yuan, with a rolling PE ratio of 14.90 times and a total market capitalization of 3.21 billion yuan [1] - The average PE ratio for the medical device industry is 48.71 times, with a median of 35.37 times, placing Kangdai at the 34th position within the industry [1][2] Group 2 - As of the first quarter of 2025, seven institutions hold shares in Kangdai, with a total of 197.34 million shares valued at 1.446 billion yuan [1] - Kangdai's main business includes the research, production, sales, and service of medical devices such as puncture needles and infusion devices, with a diverse product range [1] - The latest financial report for the first quarter of 2025 shows Kangdai achieved a revenue of 548 million yuan, a year-on-year decrease of 3.82%, and a net profit of 60.70 million yuan, a year-on-year increase of 0.28%, with a gross profit margin of 32.02% [1]

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Kangdelai, a company in the medical device industry, which has a current PE ratio of 15.12, significantly lower than the industry average of 49.51 [1][2] - As of March 31, 2025, Kangdelai has 25,817 shareholders, a decrease of 822 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - The company specializes in the research, production, and sales of medical devices, including puncture needles and infusion devices, with its R&D centers recognized at both municipal and provincial levels [1] Group 2 - In the latest quarterly report for Q1 2025, Kangdelai reported a revenue of 548 million yuan, a year-on-year decrease of 3.82%, and a net profit of 60.70 million yuan, with a slight increase of 0.28% [1] - The gross profit margin for the company stands at 32.02%, indicating its profitability in the current market conditions [1] - The company ranks 35th in terms of PE ratio within its industry, reflecting its relative valuation compared to peers [2]